PDCD1 and neoplasm: In the present study, we established a dextran sulfate sodium (DSS)-induced colitis and B16 melanoma tumor mouse model to imitate the clinical outcomes of patients receiving ipilimumab (Anti-CTLA-4) and nivolumab (anti-PD-1), for whom colitis is the most frequent problem encountered.